Navigation Links
Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome
Date:7/23/2014

CARLSBAD, Calif., July 23, 2014 /PRNewswire/ -- Essentialis announced today the receipt of a grant from the Foundation for Prader-Willi Research (FPWR) to support clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. The clinical study is being conducted at the University of California, Irvine under the direction of Dr. Virginia Kimonis.

"We have found that the support of FPWR extends well beyond the grant. They have actively promoted this clinical study through their extensive connections in the Prader-Willi community, increasing the pace of recruitment, and they shared the input of experts, improving the design of the clinical study," said Dr. Neil M. Cowen, President and Chief Scientific Officer of Essentialis. 

"FPWR is looking forward to the results of clinical study PC025 and to the further development of DCCR in the treatment of Prader-Willi syndrome where it has the potential to address a significant unmet medical need," said Dr. Theresa V. Strong, chair of the FPWR Scientific Advisory Board. "This is the first time FPWR has provided funding to a company developing a drug to treat PWS."

About DCCR DCCR is a proprietary crystalline salt of diazoxide formulated as a controlled-release, once-a-day tablet. It is in development for the treatment of Prader-Willi syndrome and hypothalamic obesity. DCCR is covered by multiple issued US and granted EU and Japanese patents, which provide composition of matter protection until 2028. Essentialis is globally prosecuting claims to the use of pharmaceutical formulations of KATP channel activators including diazoxide and DCCR in the treatment of Prader-Willi syndrome. Essentialis has evaluated DCCR in more than 200 subjects in multiple double-blind, placebo-controlled studies. More information about clinical study PC025 can be found at www.clinicaltrials.gov using identifier NCT02034071.

About FPWR The Foundation for Prader-Willi Research was established in 2003 by a small group of parents who saw the need to foster research that would help their children with Prader-Willi syndrome lead more healthy and fulfilling lives. Today, FPWR is composed of hundreds of parents, family members, researchers, and others who are interested in addressing the many issues related to PWS, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders.  The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research. For more information visit http://www.fpwr.org/

About Essentialis, Inc. Essentialis is a Carlsbad-based, orphan drug focused, pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has the potential to treat and prevent a wide range of metabolic, CNS and cardiovascular diseases.

For more information visit http://essentialistherapeutics.com/.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. DICOM Grid Secures $6 Million to Meet Growing Demand for Digital Medical Imaging in the Cloud
2. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
3. Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
4. Liberty Design Secures GSA Award, to Supply Federal Agencies
5. Sanomedics Secures $5 Million Revolving Credit Facility With TCA Global Credit Master Fund, LP To Fund Growth And Future Acquisitions
6. Halozyme Secures Additional $20 Million Term Loan
7. AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
8. Total Artificial Heart Manufacturer SynCardia Secures $14M in Growth Financing
9. Zafgen Secures $45 Million in Series E Financing
10. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
11. Calithera Biosciences Secures $35 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... , March 27, 2017  A new survey ... found that Medicare,s Competitive Bidding Program (CBP) significantly reduced ... supplies. The lack of choice forces beneficiaries to switch ... dire health consequences. AADE,s survey is ... AADE and others pointing out the inherent problems with ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 FinancialBuzz.com ... According to a ... North America , grew 34 percent to $6.7 billion ... growth rate of (CAGR) over the next five years, from $6.7 billion ... portion of Americans that will be able to purchase cannabis without a ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists ... to quality care can be limited while the desire to conquer breakouts and eliminate ... acne care for every customer online, today released its inaugural survey on the State ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort to ... recently developed and published an informational resource that addresses frequently asked questions. ... inquiries the site’s team of third party administrator (TPA) contributors regularly receives as ...
(Date:3/28/2017)... ... 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in ... the country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics ... Harper helped propel the clinic from a small start-up to number 78 in the ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn placements ... channels. , While many results are clear, much of PR is hard to quantify. ... it comes to measurement, firms should always take an all-inclusive approach that takes both ...
Breaking Medicine News(10 mins):